Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2016

01-11-2016 | Original Article

Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping

Authors: Alyce J. M. Anderson, Benjamin Click, Claudia Ramos-Rivers, Dmitriy Babichenko, Ioannis E. Koutroubakis, Douglas J. Hartman, Jana G. Hashash, Marc Schwartz, Jason Swoger, Arthur M. Barrie III, Michael A. Dunn, Miguel Regueiro, David G. Binion

Published in: Digestive Diseases and Sciences | Issue 11/2016

Login to get access

Abstract

Background

Inflammatory bowel disease (IBD) is a heterogeneous collection of chronic inflammatory disorders of the digestive tract. Clinical, genetic, and pathological heterogeneity makes it increasingly difficult to translate efficacy studies into real-world practice. Our objective was to develop a comprehensive natural history registry derived from multi-year observational data to facilitate effectiveness and clinical phenotypic research in IBD.

Methods

A longitudinal, consented registry with prospectively collected data was developed at UPMC. All adult IBD patients receiving care at the tertiary care center of UPMC are eligible for enrollment. Detailed data in the electronic health record are accessible for registry research purposes. Data are exported directly from the electronic health record and temporally organized for research.

Results

To date, there are over 2565 patients participating in the IBD research registry. All patients have demographic data, clinical disease characteristics, and disease course data including healthcare utilization, laboratory values, health-related questionnaires quantifying disease activity and quality of life, and analytical information on treatment, temporally organized for 6 years (2009–2015). The data have resulted in a detailed definition of clinical phenotypes suitable for association studies with parameters of disease outcomes and treatment response. We have established the infrastructure required to examine the effectiveness of treatment and disease course in the real-world setting of IBD.

Conclusions

The IBD research registry offers a unique opportunity to investigate clinical research questions regarding the natural course of the disease, phenotype association studies, effectiveness of treatment, and quality of care research.
Literature
1.
go back to reference Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46.e42–54.e42. quiz e30.CrossRef Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46.e42–54.e42. quiz e30.CrossRef
2.
go back to reference Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.CrossRefPubMedPubMedCentral Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.CrossRefPubMedPubMedCentral
3.
go back to reference Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003;98:1064–1072.PubMed Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003;98:1064–1072.PubMed
4.
go back to reference Bernstein CN, Nugent Z, Targownik LE, Singh H, Lix LM. Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut. 2015;64:1403–1411.CrossRefPubMed Bernstein CN, Nugent Z, Targownik LE, Singh H, Lix LM. Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut. 2015;64:1403–1411.CrossRefPubMed
5.
go back to reference Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;1:1002–1007.CrossRef Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;1:1002–1007.CrossRef
6.
go back to reference Gonzaga JE, Ananthakrishnan AN, Issa M, et al. Durability of infliximab in Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2009;15:1837–1843.CrossRefPubMed Gonzaga JE, Ananthakrishnan AN, Issa M, et al. Durability of infliximab in Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2009;15:1837–1843.CrossRefPubMed
7.
go back to reference Chaparro M, Panes J, García V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol. 2011;1:113–118.CrossRef Chaparro M, Panes J, García V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol. 2011;1:113–118.CrossRef
8.
go back to reference Chaparro M, Panés J, García V, et al. Long-term durability of response to adalimumab in Crohn’s disease. Inflamm Bowel Dis. 2012;1:685–690.CrossRef Chaparro M, Panés J, García V, et al. Long-term durability of response to adalimumab in Crohn’s disease. Inflamm Bowel Dis. 2012;1:685–690.CrossRef
9.
go back to reference Irvine EJ, Zhou Q, Thompson AK. The short inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.PubMed Irvine EJ, Zhou Q, Thompson AK. The short inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.PubMed
10.
go back to reference Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;8:514.CrossRef Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;8:514.CrossRef
11.
go back to reference Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease [Internet]. Ann Intern Med. 1989;1:353–356.CrossRef Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease [Internet]. Ann Intern Med. 1989;1:353–356.CrossRef
12.
go back to reference R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, R Foundation for Statistical Computing, [cited 2015 Oct 12]. http://www.R-project.org; 2013. R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, R Foundation for Statistical Computing, [cited 2015 Oct 12]. http://​www.​R-project.​org; 2013.
16.
go back to reference Tseytlin E, Mitchell K, Legowski E, Corrigan J, Chavan G, Jacobson RS. NOBLE—flexible concept recognition for large-scale biomedical natural language processing. BMC Bioinform. 2016;14:32.CrossRef Tseytlin E, Mitchell K, Legowski E, Corrigan J, Chavan G, Jacobson RS. NOBLE—flexible concept recognition for large-scale biomedical natural language processing. BMC Bioinform. 2016;14:32.CrossRef
17.
go back to reference Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;1:119–124.CrossRef Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;1:119–124.CrossRef
18.
go back to reference Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;1:1461–1463.CrossRef Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;1:1461–1463.CrossRef
19.
go back to reference Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5A–36A.CrossRefPubMed Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5A–36A.CrossRefPubMed
20.
go back to reference Ramos-Rivers C, Regueiro M, Vargas EJ, et al. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:986–94.CrossRefPubMed Ramos-Rivers C, Regueiro M, Vargas EJ, et al. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:986–94.CrossRefPubMed
22.
go back to reference Koutroubakis IE, Ramos-Rivers C, Regueiro M, et al. Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:1760–1766.CrossRefPubMedPubMedCentral Koutroubakis IE, Ramos-Rivers C, Regueiro M, et al. Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:1760–1766.CrossRefPubMedPubMedCentral
23.
go back to reference Click BH, Machicado JD, Rivers CR, et al. Su1334 Eosinophilia in patients with inflammatory bowel disease is independently associated with increased healthcare expenditures: a prospective 5-year experience. Gastroenterology. 2015;148:S-477–S-478.CrossRef Click BH, Machicado JD, Rivers CR, et al. Su1334 Eosinophilia in patients with inflammatory bowel disease is independently associated with increased healthcare expenditures: a prospective 5-year experience. Gastroenterology. 2015;148:S-477–S-478.CrossRef
24.
go back to reference Machicado JD, Kabbani T, Rivers CR, et al. Sa1187 peripheral blood eosinophilia in patients with inflammatory bowel disease is associated with worse outcomes: A 5-year prospective study. Gastroenterology. 2015;S-148:S-251.CrossRef Machicado JD, Kabbani T, Rivers CR, et al. Sa1187 peripheral blood eosinophilia in patients with inflammatory bowel disease is associated with worse outcomes: A 5-year prospective study. Gastroenterology. 2015;S-148:S-251.CrossRef
25.
go back to reference Johnson C, Hartman DJ, Rivers CR, et al. Sa1876 do epithelioid granulomas function as a biomarker of severity in Crohn’s disease? Analysis of a prospective six-year natural history registry. Gastroenterology. 2016;150:S387–S388.CrossRef Johnson C, Hartman DJ, Rivers CR, et al. Sa1876 do epithelioid granulomas function as a biomarker of severity in Crohn’s disease? Analysis of a prospective six-year natural history registry. Gastroenterology. 2016;150:S387–S388.CrossRef
26.
go back to reference Anderson AJ, Rivers CR, Click BH, et al. Su1810 clostridium difficile Infection in inflammatory bowel disease predicts future healthcare utilization. Gastroenterology. 2016;150:S559.CrossRef Anderson AJ, Rivers CR, Click BH, et al. Su1810 clostridium difficile Infection in inflammatory bowel disease predicts future healthcare utilization. Gastroenterology. 2016;150:S559.CrossRef
27.
go back to reference Click B, Ramos Rivers C, Koutroubakis IE, et al. Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1442–1449.CrossRefPubMed Click B, Ramos Rivers C, Koutroubakis IE, et al. Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1442–1449.CrossRefPubMed
28.
go back to reference Atreja A, Achkar JP, Jain AK, Harris CM, Lashner BA. Using technology to promote gastrointestinal outcomes research: a case for electronic health records. Am J Gastroenterol. 2008;103:2171–2178.CrossRefPubMed Atreja A, Achkar JP, Jain AK, Harris CM, Lashner BA. Using technology to promote gastrointestinal outcomes research: a case for electronic health records. Am J Gastroenterol. 2008;103:2171–2178.CrossRefPubMed
29.
go back to reference Sox HC. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;4:203.CrossRef Sox HC. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;4:203.CrossRef
30.
go back to reference Ali UA, Issa Y, van Goor H, et al. Dutch Chronic Pancreatitis Registry (CARE): design and rationale of a nationwide prospective evaluation and follow-up. Pancreatology. 2015;15:46–52.CrossRef Ali UA, Issa Y, van Goor H, et al. Dutch Chronic Pancreatitis Registry (CARE): design and rationale of a nationwide prospective evaluation and follow-up. Pancreatology. 2015;15:46–52.CrossRef
31.
go back to reference Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252–261.CrossRefPubMed Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252–261.CrossRefPubMed
32.
go back to reference Hye RJ, Inui TS, Anthony FF, et al. A multiregional registry experience using an electronic medical record to optimize data capture for longitudinal outcomes in endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2015;61:1160–1166.CrossRefPubMed Hye RJ, Inui TS, Anthony FF, et al. A multiregional registry experience using an electronic medical record to optimize data capture for longitudinal outcomes in endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2015;61:1160–1166.CrossRefPubMed
33.
go back to reference Schmitt-Egenolf M. PsoReg–the Swedish registry for systemic psoriasis treatment. The registry’s design and objectives. Dermatology (Basel). 2007;214:112–117. Schmitt-Egenolf M. PsoReg–the Swedish registry for systemic psoriasis treatment. The registry’s design and objectives. Dermatology (Basel). 2007;214:112–117.
34.
go back to reference Papp KA, Strober B, Augustin M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11:1210–1217.PubMed Papp KA, Strober B, Augustin M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11:1210–1217.PubMed
35.
go back to reference Liao KP, Ananthakrishnan AN, Kumar V, et al. Methods to develop an electronic medical record phenotype algorithm to compare the risk of coronary artery disease across 3 chronic disease cohorts. PLoS One. 2015;24:e0136651.CrossRef Liao KP, Ananthakrishnan AN, Kumar V, et al. Methods to develop an electronic medical record phenotype algorithm to compare the risk of coronary artery disease across 3 chronic disease cohorts. PLoS One. 2015;24:e0136651.CrossRef
36.
go back to reference Ananthakrishnan AN, Cagan A, Cai T, et al. Identification of nonresponse to treatment using narrative data in an electronic health record inflammatory bowel disease cohort. Inflamm Bowel Dis. 2016;22:151–158.CrossRefPubMed Ananthakrishnan AN, Cagan A, Cai T, et al. Identification of nonresponse to treatment using narrative data in an electronic health record inflammatory bowel disease cohort. Inflamm Bowel Dis. 2016;22:151–158.CrossRefPubMed
37.
go back to reference Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–396.CrossRefPubMed Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–396.CrossRefPubMed
38.
go back to reference Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012;87:1196–1201.CrossRefPubMedPubMedCentral Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012;87:1196–1201.CrossRefPubMedPubMedCentral
39.
go back to reference Hamilton CM, Strader LC, Pratt JG, et al. The PhenX toolkit: get the most from your measures. Am J Epidemiol. 2011;1:253–260.CrossRef Hamilton CM, Strader LC, Pratt JG, et al. The PhenX toolkit: get the most from your measures. Am J Epidemiol. 2011;1:253–260.CrossRef
40.
go back to reference Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. Am J Gastroenterol. 2016;111:712–719.CrossRefPubMed Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. Am J Gastroenterol. 2016;111:712–719.CrossRefPubMed
42.
go back to reference Loftus CG, Loftus EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.CrossRefPubMed Loftus CG, Loftus EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.CrossRefPubMed
43.
go back to reference Sands BE, LeLeiko N, Shah SA, Bright R, Grabert S. OSCCAR: ocean state Crohn’s and colitis area registry. Med Health R I. 2009;92:88. Sands BE, LeLeiko N, Shah SA, Bright R, Grabert S. OSCCAR: ocean state Crohn’s and colitis area registry. Med Health R I. 2009;92:88.
44.
go back to reference Moran GW, Dubeau MF, Kaplan GG, et al. Phenotypic features of Crohn’s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2014;12:434–442.CrossRefPubMed Moran GW, Dubeau MF, Kaplan GG, et al. Phenotypic features of Crohn’s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2014;12:434–442.CrossRefPubMed
45.
go back to reference Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999;15:916–924.CrossRef Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999;15:916–924.CrossRef
46.
go back to reference Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008;103:1451–1459.CrossRefPubMed Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008;103:1451–1459.CrossRefPubMed
47.
go back to reference Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–976.PubMed Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–976.PubMed
49.
go back to reference Koutroumpakis E, Ramos-Rivers C, Regueiro M, et al. Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2015. doi:10.1007/s10620-015-3932-1.PubMed Koutroumpakis E, Ramos-Rivers C, Regueiro M, et al. Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2015. doi:10.​1007/​s10620-015-3932-1.PubMed
Metadata
Title
Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping
Authors
Alyce J. M. Anderson
Benjamin Click
Claudia Ramos-Rivers
Dmitriy Babichenko
Ioannis E. Koutroubakis
Douglas J. Hartman
Jana G. Hashash
Marc Schwartz
Jason Swoger
Arthur M. Barrie III
Michael A. Dunn
Miguel Regueiro
David G. Binion
Publication date
01-11-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4278-z

Other articles of this Issue 11/2016

Digestive Diseases and Sciences 11/2016 Go to the issue